THE CLAUDIN-1 COMPANY
Treat cancer and reverse fibrosis
We are a biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our clinical pipeline of anti-Claudin-1 monoclonal antibodies.
Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.
Transformative Claudin-1 antibodies
We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.
R&D pipeline
We have developed a promising pipeline of anti-Claudin-1 antibodies. Our two clinical candidates are in Phase 1/2 for solid tumors and Phase 2 for organ fibrosis, respectively. Beyond conventional therapies, our preclinical programs feature anti-Claudin-1 antibody-drug conjugates, bispecific antibodies, and T-cell engagers.
Inspired leadership
Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.
Alentis news
January 08, 2024
WILLIAM PAO JOINS ALENTIS THERAPEUTICS AS INDEPENDENT BOARD MEMBER